目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院...目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院的体检健康者51例作为对照组。依据梗死病灶范围将脑梗死患者分为大梗死组(梗死病灶>50 cm 2),中梗死组(梗死病灶在10~50 cm 2),小梗死组(梗死病灶<10 cm 2)。依据颈动脉彩超结果将脑梗死患者分为斑块期组、增厚期组、管壁正常组。采用酶联免疫吸附试验检测血清ZO-1、aβ2-GP1水平,并比较各组ZO-1、aβ2-GP1水平变化;采用Spearman相关分析脑梗死患者血清ZO-1、aβ2-GP1水平与梗死病灶范围及颈动脉粥样硬化程度的相关性。结果研究组血清ZO-1水平低于对照组,血清aβ2-GP1水平高于对照组(P<0.05)。在103例脑梗死患者中,大梗死组有32例,中梗死组有34例,小梗死组有37例,其中小梗死组ZO-1水平高于中梗死组和大梗死组,aβ2-GP1水平低于中梗死组和大梗死组(P<0.05);中梗死组ZO-1水平高于大梗死组,aβ2-GP1水平低于大梗死组(P<0.05)。在103例脑梗死患者中,斑块期组有29例,增厚期组有38例,管壁正常组有36例,其中斑块期组血清ZO-1水平低于增厚期组和管壁正常组,aβ2-GP1水平高于增厚期组和管壁正常组(P<0.05);增厚期组血清ZO-1水平低于管壁正常组,aβ2-GP1水平高于管壁正常组(P<0.05)。Spearman相关分析发现,脑梗死患者血清ZO-1水平与颈动脉粥样硬化程度和梗死病灶范围呈负相关(P<0.05),aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围呈正相关(P<0.05)。结论脑梗死患者血清ZO-1和aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围有着明显的相关性,在脑梗死患者的病情诊断、治疗和预后中具有潜在价值。展开更多
Type 1 diabetes can be classified into immune-mediated diabetes (type 1A) and idiopathic diabetes, which lacks immunological evidence for beta cell autoimmunity (type 1B). Type 1A diabetes is characterized by the pres...Type 1 diabetes can be classified into immune-mediated diabetes (type 1A) and idiopathic diabetes, which lacks immunological evidence for beta cell autoimmunity (type 1B). Type 1A diabetes is characterized by the presence of the anti-glutamic acid decarboxylase antibody (anti-GADab). Fulminant type 1 diabetes is classified as type 1B diabetes, and characterized by the absence of anti-GADab, flu-like symptoms, and elevated serum exocrine pancreatic enzymes. We report a type 1 diabetic patient who showed flu-like symptoms, elevated serum exocrine pancreatic enzymes, and an extremely high-titer of anti-GADab, manifesting the characteristics of both type 1A and fulminant type 1 diabetes.展开更多
Aims: This paper investigates the presence of M3 muscarinic acetylcholine receptor autoantibody present in the serum of patients with primary Sj?gren syndrome (pSS). Main methods: We detected the levels of M3mAChR pep...Aims: This paper investigates the presence of M3 muscarinic acetylcholine receptor autoantibody present in the serum of patients with primary Sj?gren syndrome (pSS). Main methods: We detected the levels of M3mAChR peptide IgG, PGE2, IL-1β in serum of SS patients using the enzyme-linked immune sorbent assay (ELISA). To measure the quantity of nitrite/nitrate, we used Griess reagent system. Key findings: Titres of M3mAChR antibody in sera from SS patients are significantly enhanced compared to healthy subjects (control). The enhancement of these autoantibodies is accompanied by the increase of the levels of PGE2, IL-1β and nitrite/nitrate in serum. Under in vitro conditions, the synthetic human M3 peptide impaires the increment of M3mAChR antibody but not that of nati-Ro/SSA antibody. In positive anti-Ro/SSA antibody patients, the increment of M3mAChR peptide IgG and the measured pro-inflammatory substances is related. Significance: On this basis, anti M3mAChR peptide IgG can be said to act as a modulator of the immune system and to play a role in the host-chronic increment of proinflammatory substances in SS patients with positive Ro/SSA antibody. This association between the antibody and the pathogenesis of SS disease may result in useful predicting SS.展开更多
文摘目的分析tau蛋白、胶质纤维状酸性蛋白(glial fibrillary acidic protein,GFAP)以及抗β2糖蛋白1抗体(anti-β2 glycoprotein 1 antibody,aβ2-GP1)水平与高血压脑出血(hypertensive intracerebral hemorrhage,HICH)患者预后的相关性。方法将70例HICH患者纳入研究组,另将同时期进行健康体检的70例人员纳入对照组。比较两组tau蛋白、GFAP以及aβ2-GP1水平。比较不同预后HICH患者tau蛋白、GFAP、aβ2-GP1水平和美国国立卫生院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分;并分析HICH患者相关指标与NIHSS评分的相关性。使用受试者工作特征(receiver operation characteristic,ROC)曲线分析相关指标预测HICH患者不良预后的临床价值。结果与对照组比较,观察组tau蛋白、GFAP以及aβ2-GP1水平均较高(P<0.05)。预后不良的HICH患者tau蛋白、GFAP、aβ2-GP1水平和NIHSS评分均较高(P<0.05);相关指标与NIHSS评分均呈正相关(均P<0.05)。相关指标预测HICH患者预后不良的最佳临界值:tau蛋白≥258.15ng/L、GFAP≥16.15ng/L、aβ2-GP1≥18.35 RU/mL,此时ROC曲线下面积(area under the curve,AUC)为0.908(95%CI:0.828~0.988,P<0.05)、0.871(95%CI:0.781~0.961,P<0.05)、0.839(95%CI:0.728~0.949,P<0.05),敏感度为77.27%、77.27%、72.73%,特异度为97.92%、85.42%、89.58%。结论HICH患者tau蛋白、GFAP以及aβ2-GP1水平较高,神经损伤较重、预后不良的HICH患者相关指标更高,监测HICH患者tau蛋白、GFAP以及aβ2-GP1水平可用于不良预后的评估。
文摘目的探讨血清闭锁小带蛋白1(ZO-1)、抗β2糖蛋白1抗体(aβ2-GP1)水平与脑梗死患者梗死病灶范围及颈动脉粥样硬化程度的相关性。方法选取2020年1月至2023年1月于保定市第一中心医院进行治疗的脑梗死患者103例作为研究组,另选取同期该院的体检健康者51例作为对照组。依据梗死病灶范围将脑梗死患者分为大梗死组(梗死病灶>50 cm 2),中梗死组(梗死病灶在10~50 cm 2),小梗死组(梗死病灶<10 cm 2)。依据颈动脉彩超结果将脑梗死患者分为斑块期组、增厚期组、管壁正常组。采用酶联免疫吸附试验检测血清ZO-1、aβ2-GP1水平,并比较各组ZO-1、aβ2-GP1水平变化;采用Spearman相关分析脑梗死患者血清ZO-1、aβ2-GP1水平与梗死病灶范围及颈动脉粥样硬化程度的相关性。结果研究组血清ZO-1水平低于对照组,血清aβ2-GP1水平高于对照组(P<0.05)。在103例脑梗死患者中,大梗死组有32例,中梗死组有34例,小梗死组有37例,其中小梗死组ZO-1水平高于中梗死组和大梗死组,aβ2-GP1水平低于中梗死组和大梗死组(P<0.05);中梗死组ZO-1水平高于大梗死组,aβ2-GP1水平低于大梗死组(P<0.05)。在103例脑梗死患者中,斑块期组有29例,增厚期组有38例,管壁正常组有36例,其中斑块期组血清ZO-1水平低于增厚期组和管壁正常组,aβ2-GP1水平高于增厚期组和管壁正常组(P<0.05);增厚期组血清ZO-1水平低于管壁正常组,aβ2-GP1水平高于管壁正常组(P<0.05)。Spearman相关分析发现,脑梗死患者血清ZO-1水平与颈动脉粥样硬化程度和梗死病灶范围呈负相关(P<0.05),aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围呈正相关(P<0.05)。结论脑梗死患者血清ZO-1和aβ2-GP1水平与颈动脉粥样硬化程度和梗死病灶范围有着明显的相关性,在脑梗死患者的病情诊断、治疗和预后中具有潜在价值。
文摘Type 1 diabetes can be classified into immune-mediated diabetes (type 1A) and idiopathic diabetes, which lacks immunological evidence for beta cell autoimmunity (type 1B). Type 1A diabetes is characterized by the presence of the anti-glutamic acid decarboxylase antibody (anti-GADab). Fulminant type 1 diabetes is classified as type 1B diabetes, and characterized by the absence of anti-GADab, flu-like symptoms, and elevated serum exocrine pancreatic enzymes. We report a type 1 diabetic patient who showed flu-like symptoms, elevated serum exocrine pancreatic enzymes, and an extremely high-titer of anti-GADab, manifesting the characteristics of both type 1A and fulminant type 1 diabetes.
文摘Aims: This paper investigates the presence of M3 muscarinic acetylcholine receptor autoantibody present in the serum of patients with primary Sj?gren syndrome (pSS). Main methods: We detected the levels of M3mAChR peptide IgG, PGE2, IL-1β in serum of SS patients using the enzyme-linked immune sorbent assay (ELISA). To measure the quantity of nitrite/nitrate, we used Griess reagent system. Key findings: Titres of M3mAChR antibody in sera from SS patients are significantly enhanced compared to healthy subjects (control). The enhancement of these autoantibodies is accompanied by the increase of the levels of PGE2, IL-1β and nitrite/nitrate in serum. Under in vitro conditions, the synthetic human M3 peptide impaires the increment of M3mAChR antibody but not that of nati-Ro/SSA antibody. In positive anti-Ro/SSA antibody patients, the increment of M3mAChR peptide IgG and the measured pro-inflammatory substances is related. Significance: On this basis, anti M3mAChR peptide IgG can be said to act as a modulator of the immune system and to play a role in the host-chronic increment of proinflammatory substances in SS patients with positive Ro/SSA antibody. This association between the antibody and the pathogenesis of SS disease may result in useful predicting SS.
